Most Read Articles
3 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
Elvira Manzano, 2 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
3 days ago
Better sleep appears to weaken pain and fatigue in older, community-dwelling adults with hip or knee osteoarthritis (OA), reports a recent study.
07 Nov 2019
Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus viraemia in transplant recipients, a study has found.

Sofosbuvir-velpatasvir combo safe, effective for HCV patients with end-stage renal disease

05 Oct 2019

The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.

Fifty-nine HCV patients (mean age, 60 years; 59 percent male) undergoing haemodialysis or peritoneal dialysis of ESRD were given open-label sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks. The primary efficacy endpoint was the proportion of participants reaching sustained virological response 12 weeks after the treatment was discontinued (SVR12). Discontinuation due to adverse events was the primary safety endpoint.

Almost all patients achieved SVR12 (95 percent; n=56). Most of the patients who achieved the primary efficacy endpoint had drug adherence rates of at least 90 percent. Those who fell short of SVR12 had adherence rates of <90 percent; one patient died of suicide after achieving viral suppression 79 days after treatment.

Adverse events were also fairly common, with 80 percent of the study population reporting at least one episode. Most were mild or moderate in severity.

The most common side effects were headache (17 percent), fatigue (14 percent), nausea (14 percent), vomiting (14 percent) and insomnia (10 percent). Eleven patients (19 percent) experienced serious adverse events, though none were deemed to be related to the study treatment. There were no discontinuations due to adverse events.

Aside from the suicide, one other death occurred due to metastatic lung cancer 111 days after completing the study.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
Elvira Manzano, 2 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
3 days ago
Better sleep appears to weaken pain and fatigue in older, community-dwelling adults with hip or knee osteoarthritis (OA), reports a recent study.
07 Nov 2019
Maribavir 400 mg twice daily appears to have comparable efficacy to valganciclovir at clearing cytomegalovirus viraemia in transplant recipients, a study has found.